Valuation
- Market cap
- 10,480,000
- Revenue TTM
- $0
- Net income TTM
- $-11,610,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 15,400
- Avg volume
- 26,660
- Day's range
- $3.21 – $3.45
- Shares out
- 3,265,000
- Stochastic %K
- 24%
- Beta
- 2.81
- Analysts
- Strong Sell
- Price target
- $18.50
Company profile
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical...
Show more
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 203 221 7381
- Website
- https://intensitytherapeutics.com
- Address
- 1 Enterprise Drive, Suite 430, Shelton, United States
Latest news
No headlines yet.
